Janney Upgrades T2 Biosystems to Buy | GenomeWeb

NEW YORK (GenomeWeb) – Janney Capital Markets today announced it has upgraded shares of T2 Biosystems to a Buy rating on the results of its first quarter financial update.

Analyst Paul Knight upgraded shares from a previous rating of Neutral and reiterated his target share price of $25 for the company's stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.